MarketPulse

NDA deficiencies

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Aquestive Therapeutics Faces Class Action Over Anaphylm FDA Approval Misstatements

Portnoy Law Firm files class action against $AQST for allegedly misleading investors about Anaphylm FDA prospects. Stock plunged 37% after deficiency disclosure.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

AQST Stock Plunged 37% After FDA Setback; Securities Lawsuit Deadline Looms May 4

Aquestive Therapeutics faces securities class action over alleged false FDA approval statements for Anaphylm drug. Stock fell 37% after January 2026 NDA rejection.
AQSTsecurities class actionmisleading statements